Patient centricity is now recognized as one of the key values in the pharmaceutical business, changing both the research and development of new drugs as well as their clinical trials and treatment. For example, a recent Deloitte report revealed ...
Read MoreJEDDAH, Saudi Arabia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) in Jeddah successfully performed the first robotic liver transplant in the Western Region on a 23-year-old man suffering from ...
Read MoreNEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced the launch of its innovative next-gen program, introducing advanced features designed to make weight management ...
Read MoreOSLO, Norway and BURLINGAME, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy’s innovative cloud-based data-sharing platform could accelerate access to vaccines and other health technologies by enabling multi-country regulatory ...
Read MoreBENGALURU, India, Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a pioneering Bengaluru-based biotechnology company, has successfully closed its seed funding round backed by angel investors. This funding will ...
Read MoreAIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, ...
Read MorePatient centricity is now recognized as one of the key values in the pharmaceutical business, changing both the research and development of new drugs as well as their clinical trials and treatment. For example, a recent Deloitte report revealed ...
Read MorePR Newswire NEW YORK, Dec. 11, 2024 NEW YORK, Dec. 11, 2024 /PRNewswire/ -- A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies, today ...
Read MorePR Newswire NEW YORK, Dec. 11, 2024 NEW YORK, Dec. 11, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global heparin market size is estimated to grow by USD 3.34 billion from 2024-2028, according to Technavio. The ...
Read MorePR Newswire LAS VEGAS, Dec. 11, 2024 T-cell malignancies account for about 10-15% of all lymphoid malignancies, and their treatment often involves chemotherapy, immunotherapy, or stem cell transplantation. These cancers can be particularly ...
Read MorePR Newswire TAMPA, Fla., Dec. 11, 2024 The region's only university-affiliated academic health system is acknowledged for its continued commitment to providing exceptional maternity, childbirth and postpartum care. TAMPA, Fla., Dec. 11, ...
Read MorePR Newswire NEW YORK, Dec. 11, 2024 NEW YORK, Dec. 11, 2024 /PRNewswire/ -- Ready. Set. Food!, a leader in early allergen introduction solutions, and ObvioHealth, a global leader in digital clinical trial solutions, are proud to announce the ...
Read MoreCanada NewsWire TORONTO, Dec. 11, 2024 New report finds drug claims for chronic diseases like diabetes and high blood pressure on the rise TORONTO, Dec. 11, 2024 /CNW/ - Chronic diseases don't discriminate when it comes to age. A new ...
Read MorePR Newswire DALLAS, Dec. 11, 2024 Surgery utilizes Levita MARS Platform and its Dynamic Magnetic Positioning™ technology and Da Vinci Single Port Robotic System to deliver unprecedented precision and set a new standard for minimally invasive ...
Read MorePR Newswire EAGAN, Minn., Dec. 11, 2024 The new Flyte App and Provider Portal offer enhanced tracking and personalization for women suffering from mild to severe SUI, improving care outcomes and provider-patient collaboration EAGAN, ...
Read MorePR Newswire SEOUL, South Korea, Dec. 11, 2024 ** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Multinational Phase 3 Clinical Trial ...
Read MorePR Newswire FORT WORTH, Texas, Dec. 11, 2024 TimelyCare survey highlights mental health and financial challenges impacting college and university students. FORT WORTH, Texas, Dec. 11, 2024 /PRNewswire/ -- A recent survey by TimelyCare, ...
Read MorePR Newswire CAMBRIDGE, Mass., Dec. 11, 2024 CAMBRIDGE, Mass., Dec. 11, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
Read MorePR Newswire CAMBRIDGE, Mass., Dec. 11, 2024 Dynocardia's proprietary computer-vision technology effectively identifies and compensates for movement artifacts. Overcoming these artifacts has long been a significant challenge in accurately ...
Read MorePR Newswire SANTA CRUZ, Calif., Dec. 11, 2024 Led by Eclipse, the round will further allow the company to bring the benefits of robotics to one of the few remaining untouched areas of medicine and structural heart SANTA CRUZ, Calif., ...
Read MorePR Newswire SAN DIEGO, Dec. 11, 2024 Cohort Outperforms National Averages, Setting a New Standard for Diabetes Prevention for Employers and Health Plans SAN DIEGO, Dec. 11, 2024 /PRNewswire/ -- 9amHealth, the leading virtual ...
Read MorePR Newswire MASON, Ohio, Dec. 11, 2024 Proactive, personalized monitoring of myocardial fitness at regular intervals, powered by MCG technology, represents paradigm shift in the prevention of heart disease City of Mason's Biohealth ...
Read MoreCanada NewsWire TORONTO, Dec. 11, 2024 TORONTO, Dec. 11, 2024 /CNW/ - Kids Help Phone is thrilled to announce a transformational investment from BGIS, the leading Canadian facilities management company, in support of youth mental health ...
Read MorePR Newswire FORT LAUDERDALE, Fla., Dec. 11, 2024 FORT LAUDERDALE, Fla., Dec. 11, 2024 /PRNewswire/ -- Even during the hectic holiday season leading to Christmas and New Year's there's always extra help to give the best possible care for ...
Read MorePR Newswire INDIANAPOLIS, Dec. 11, 2024 As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations As combination therapy, ...
Read MorePR Newswire PLYMOUTH MEETING, Pa., Dec. 11, 2024 The National Comprehensive Cancer Network's Oncology Research Program's grant will advance scientific knowledge of hematologic toxicity of PARPi in the treatment of patients with prostate ...
Read MorePR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing NEW ...
Read MorePR Newswire SYDNEY, Dec. 11, 2024 SYDNEY, Dec. 11, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Breast ...
Read MorePR Newswire FORT MYERS, Fla., Dec. 11, 2024 Results of first in-human trials highlighted at global symposium FORT MYERS, Fla., Dec. 11, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologists ...
Read MorePR Newswire DURHAM, N.C., Dec. 11, 2024 DURHAM, N.C., Dec. 11, 2024 /PRNewswire/ -- Target RWE, real-world evidence leader, shared two studies at The Liver Meeting 2024 that revealed insights on the NASH-CHECK1 patient-reported outcome ...
Read MorePR Newswire ATLANTA, Dec. 11, 2024 ATLANTA, Dec. 11, 2024 /PRNewswire/ -- Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy — ET3 — for hemophilia A at the ...
Read MorePR Newswire LAUSANNE, Switzerland, Dec. 11, 2024 ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade ...
Read MorePR Newswire REDMOND, Wash., Dec. 11, 2024 - Updated safety & efficacy data in locally advanced or metastatic breast cancer patients will be presented from a phase 1 clinical study evaluating BL-B01D1, an EGFRxHER3 bispecific topoisomerase ...
Read MorePR Newswire LEXINGTON, Mass., Dec. 11, 2024 Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR solid tumors Second program targeting ...
Read MorePR Newswire EDINBURGH, Scotland, Dec. 11, 2024 EDINBURGH, Scotland, Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform ...
Read MorePR Newswire WASHINGTON, Dec. 11, 2024 WASHINGTON, Dec. 11, 2024 /PRNewswire/ -- Paragon Health Institute, a leader in healthcare research and market-based policy proposals, has released today a significant report on artificial intelligence ...
Read MoreSubscribe to our Free Newsletters!